Head and neck cancer
Head and neck cancer is the seventh most common type of cancer worldwide and comprise
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …
of a diverse group of tumours affecting the upper aerodigestive tract. Although many different …
Head and neck squamous cell carcinoma
DE Johnson, B Burtness, CR Leemans… - Nature reviews Disease …, 2020 - nature.com
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and …
Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and
occurs in the oral cavity, pharynx and larynx. Nasopharyngeal carcinoma (NPC) is a disease …
occurs in the oral cavity, pharynx and larynx. Nasopharyngeal carcinoma (NPC) is a disease …
The changing therapeutic landscape of head and neck cancer
Head and neck cancers are a heterogeneous collection of malignancies of the upper
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …
aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EEW Cohen, RB Bell, CB Bifulco, B Burtness… - … for immunotherapy of …, 2019 - Springer
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma
Background Platinum-based concurrent chemoradiotherapy is the standard of care for
patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine …
patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine …
Head and neck cancer
LQM Chow - New England Journal of Medicine, 2020 - Mass Medical Soc
Head and Neck Cancer Most head and neck cancers (73% in the United States) are now
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …
related to human papillomavirus infection rather than tobacco and alcohol. Primary cancers …
Treating head and neck cancer in the age of immunotherapy: a 2023 update
A Bhatia, B Burtness - Drugs, 2023 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …
present with locally advanced disease, requiring multimodality therapy. While this approach …
NCCN guidelines insights: head and neck cancers, version 1.2018
AD Colevas, SS Yom, DG Pfister, S Spencer… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …
recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary …